Learn, Analyse & Invest
only with
only with
+91
Download Orca
Pharmaids Pharmaceuticals Ltd.
Pharmaids Pharma
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹1.05 Cr.
| EX-Date | Purpose |
|---|---|
| 24 05 2021 | Quarterly Results |
| 23 07 2021 | Quarterly Results |
| 20 08 2021 | A.G.M. |
| 09 11 2021 | Quarterly Results |
| 28 01 2022 | Quarterly Results |
| 21 05 2022 | Audited Results |
| 22 07 2022 | Quarterly Results & A.G.M. Inter alia, to consider: 1. To approve revision in the quantum of Shares, addition of Subscribers and other matters relating to Preferential Allotment of Share Warrants, which was earlier approved by Board in their Meeting held on May 21, 2022. If approved by the Board, it is proposed to obtain the approval of the Shareholders in the ensuing AGM of the Company. 2. To consider appointment of Mr. Venu Madhava Kaparthy (DIN: 00021699) as Whole Time Director. 3. To consider appointment of Ms. Mini Manikantan (DIN: 09663184) as Whole Time Director. 4. To consider adoption of new set of Articles and Memorandum of Association of the Company, in line with the Companies Act, 2013. 5. Shifting of Registered Office to the State of Karnataka subject to requisite approvals 6. To convene 33 Annual General Meeting (AGM) and to decide the date and venue of the AGM and to consider and approve the draft Notice for convening the Annual General Meeting containing items relating to increase of Authorised Share Capital, Preferential Allotment of Warrants, and other matters. 7. To take note of the Secretarial Audit Report issued by M/s Kashinath Sahu & Co, Practicing Company Secretaries, for the Financial Year ended 31? March, 2022. 8. To consider and approve the draft Director?s Report along with the annexures for the FY 2021-2022. 9. To fix Dates of Book Closure and Record Date. 10. To consider appointment of Scrutinizer for the 33 Annual General Meeting. |
| 13 10 2022 | Issue Of Warrants |
| 09 11 2022 | Quarterly Results |
| 29 11 2022 | Preferential Issue of shares & Inter-alia to consider the following business: 1. To consider and approve increase in Authorised Share Capital of the Company. 2. To consider issue of up to 90,00,000 Equity Shares of Rs. 10/- each on preferential issue basis in accordance with the applicable provisions and subject to necessary approvals. 3. To consider appointment of Mr. Methuku Nagesh (DIN: 01634324) as an Additional Director (Independent Category) of the Company. 4. Any other item with the permission of the chair. |
| 06 12 2022 | Inter-alia to consider the following business: 1. To fix the date, time, and venue of 1st Extraordinary General Meeting (EGM) for the financial year 2022-23 of the Company and approve the EGM notice consisting of the following matters: a. Increase in Authorised Capital from Rs. 16,50,00,000/- (Sixteen Crore Fifty Lakh Only) consisting of 1,65,00,000 numbers of equity shares of Rs. 10/- (Rupees Ten each) to Rs. 30,00,00,000/- consisting of 3,00,00,000 numbers of equity shares of Rs. 10/- (Rupees Ten each). b. Preferential Issue of 84,00,000 equity shares of Rs. 10/- each in accordance with applicable provisions and subject to necessary approvals. c. To regularize the appointment of Mr. Pattamadai Natarajasarma Vijay (DIN: 00049992) as an Independent Director of the Company and confirm his appointment for a period of 5 years. d. To regularize the appointment of Mr. Methuku Nagesh (DIN: 01634324) as an Independent Director of the Company and confirm his appointment for a period of 5 years. 2. To consider and approve the scrutiniser for the said meeting, fix the cut off and e- voting dates, agencies and all other matters connected with said EGM. 3. To consider request for conversion of 27,75,000 Share Warrants and allot equity shares as per terms of issue of share warrants. 4. Any other matter with the permission of the Chairman |
| 17 01 2023 | Inter alia, to consider and approve allotment of 84,00,000 equity shares on preferential basis |
| 13 02 2023 | Quarterly Results |
| 29 05 2023 | Audited Results |
| 04 08 2023 | Quarterly Results |
| 29 08 2023 | Inter alia, to consider and approve:- 1. To appoint a Scrutinizer to ascertain Voting Process of 34th Annual General Meeting of the Company, 2. To approve draft Notice of 34th Annual General Meeting (AGM) and to decide the date, time and venue of the AGM, To consider and fix Record date and/or Book closure date for the purpose of 34th Annual General Meeting. |
| 11 11 2023 | Quarterly Results |
| 06 01 2024 | Increase in Authorised Capital & Employees Stock Option Plan & Preferential Issue of shares & Inter alia to consider the following: 1. To increase the Authorised Share Capital of the Company. 2. To alter the Object Clause of Memorandum of Association of the Company. 3. To consider and approve issuance of Equity Shares of the Company to non-promoters on preferential issue basis (Other than cash) to acquire majority stake in Adita Bio Sys Private Limited subject to approval of the shareholders in the ensuing General Meeting. 4. To consider and approve ?Pharmaids Pharmaceuticals Limited ? Employee Stock Option Scheme 2024? subject to approval of the shareholders in the ensuing General Meeting. 5. To consider and approve ?Pharmaids Pharmaceuticals Limited ? Employee Stock Purchase Scheme 2024? subject to approval of the shareholders in the ensuing General Meeting. 6. To consider and approve of offer of shares under the ?Pharmaids Pharmaceuticals Limited - Employee Stock Purchase Scheme 2024? to the Eligible Employees/ Whole-time Director(s) of the Company exceeding 1% of issued capital, subject to approval of the shareholders in the ensuing General Meeting. 7. To convene and decide the date, time and venue of 01st Extra Ordinary General Meeting (EGM) for the financial year 2023-24. 8. To approve the appointment of Scrutinizer for the said meeting, fix the cutoff date and evoting dates, agencies and all other matters connected with the EGM. 9. Any other matter with the permission of chair. |
| 12 02 2024 | Quarterly Results |
| 13 11 2024 | Quarterly Results |
| 12 02 2025 | Quarterly Results |
| 23 05 2025 | Audited Results |
| 07 08 2025 | Quarterly Results |
| 11 11 2025 | Quarterly Results |
| 12 02 2026 | Quarterly Results |
News
